We report a case of an iatrogenic congenital diaphragmatic hernia (CDH) following left pleuroamniotic shunting at 20 weeks gestation for severe left pleural effusion. The infant developed respiratory difficulty after birth and was diagnosed with left CDH on imaging with the intraoperative findings confirming the hernia to be at an unusual site and likely secondary to the shunting.

Keywords:
Fetal therapy, Chylothorax, Congenital diaphragmatic hernia, Pleural effusions, Pleuroamniotic shunt
1.
Khalek N, Johnson MP: Management of prenatally diagnosed lung lesions. Semin Pediatr Surg 2013;22:24-29.
2.
Petersen S, Kaur R, Thomas JT, Cincotta R, Gardener G: The outcome of isolated primary fetal hydrothorax: a 10-year review from a tertiary center. Fetal Diagn Ther 2013;34:69-76.
3.
Wittman BK, Martin KA, Wilson RD, Peacock D: Complications of long-term drainage of fetal pleural effusion: case report and review of the literature. Am J Perinatol 1997;14:443-447.
4.
Rodeck CH, Fisk NM, Fraser DI, Nicolini U: Long-term in utero drainage of fetal hydrothorax. N Engl J Med 1988;319:1135-1138.
5.
Brown R, Nicolaides K: Constriction band of the arm following insertion of a pleuro-amniotic shunt. Ultrasound Obstet Gynecol 2000;15:439-440.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.